PZM21 is a novel, potent and selective Gi activator with exceptional selectivity for μ opioid receptor (μOR) and minimal β-arrestin-2 recruitment with an EC50 of 1.8 nM. It is an experimental opioid analgesic drug that is being studied for the treatment of pain. PZM21 is a functionally selective μ-opioid receptor agonist which produces μ-opioid receptor mediated G protein signaling, with potency and efficacy similar to morphine, but with less β-arrestin 2 recruitment. In tests on mice, PZM21 was slightly less potent than morphine or TRV130 as an analgesic, but also had significantly reduced adverse effects, with less constipation than morphine, and very little respiratory depression, even at high doses.

纯度：≥98%

CAS：1997387-43-5